Contemporary Role of Percutaneous Coronary Intervention on the Spectrum of Coronary Artery Disease

Contemporary Role of Percutaneous Coronary Intervention on the Spectrum of Coronary Artery Disease, Abdallah Bitar, M.D. PhD, Interventional Cardiology, Sands-Constellation Heart Institute, Rochester Regional Health. Outline: Identify and review the spectrum coronary artery disease (CAD) and how patients present differently Review recent randomized controlled trials (RCTs) on management of subsets of CAD Using case presentations, highlight current management for patients with CAD Showcase advanced PCI techniques for revascularization of chronic total occlusion

Les aspects juridiques des hyperliens

NANTES-BU Droit (441092103) / SudocSudocFranceF

Progress toward the total synthesis of roseophilin

Thesis (Ph. D.)--University of Rochester. Dept. of Chemistry, 2009.[Could not render

Post-Plasma Catalysis for Trichloroethylene Abatement with Ce-Doped Birnessite Downstream DC Corona Discharge Reactor

International audienceTrichloroethylene (TCE) removal was investigated in a post-plasma catalysis (PPC) configuration in nearly dry air (RH = 0.7%) and moist air (RH = 15%), using, for non-thermal plasma (NTP), a 10-pin-to-plate negative DC corona discharge and, for PPC, Ce0.01Mn as a catalyst, calcined at 400 °C (Ce0.01Mn-400) or treated with nitric acid (Ce0.01Mn-AT). One of the key points was to take advantage of the ozone emitted from NTP as a potential source of active oxygen species for further oxidation, at a very low temperature (100 °C), of untreated TCE and of potential gaseous hazardous by-products from the NTP. The plasma-assisted Ce0.01Mn-AT catalyst presented the best CO2 yield in dry air, with minimization of the formation of gaseous chlorinated by-products. This result was attributed to the high level of oxygen vacancies with a higher amount of Mn3+, improved specific surface area and strong surface acidity. These features also allow the promotion of ozone decomposition efficiency. Both catalysts exhibited good stability towards chlorine. Ce0.01Mn-AT tested in moist air (RH = 15%) showed good stability as a function of time, indicating good water tolerance also

Percutaneous Intervention of LVAD Outflow Graft Obstruction and Thrombosis

Left ventricular assist devices serve as a salvage therapy for patients with advanced heart failure. Complications such as thrombosis and obstruction can lead to acute device malfunction, posing significant clinical risks. A multidisciplinary approach is crucial for management. Few cases in the literature have demonstrated the safety and efficacy of percutaneous intervention, which holds significant value due to its less invasive nature and minimal risk of morbidity, especially in high-risk surgical patients

Nitric-acid treated Ce modified birnessite-type MnO2 design for ozone decomposition at low temperature: Effect of co-pollutants and water

National audienc

Acid treated Ce modified birnessite-type MnO2 for ozone decomposition at low temperature : effect of nitrogen containing co-pollutants and water

In this study, HNO3 treated Ce modified birnessite-type MnO2 (CexMn-AT; x = 0.01,0.1,0.2,0.5) have been designed for decomposition of ozone at low temperature (20-40 degrees C) in the absence or presence of nitrogen containing co-pollutants and water. The best catalyst Ce0.01Mn-AT exhibits stable ozone conversion of 94 % in nearly dry air (300 ppm of ozone, RH = 0.7 %, GHSV = 1200 L/(g.h), 20 degrees C) in the presence of N2O5/HNO3 pollutants. However, the ozone conversion drops to 64 % for the undoped catalyst showing the beneficial role of cerium. Additionally, the Ce0.1Mn-AT catalyst shows a stable ozone conversion of 91 % after 5 h on stream in moist air (RH = 30 %, 30 degrees C) in the same operating conditions as before. The high tolerance of the best acidtreated catalysts to co-pollutants and water can be explained by the high density of acid sites and oxygen vacancies which facilitate the adsorption and decomposition of ozone and allow to minimize the amount of nitrogen containing adspecies which can affect the catalytic performances for ozone decomposition

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon

Ovarian cancer is the most lethal gynecologic cancer. The high grade serous epithelial (HGSE) subtype is the most aggressive and it often presents at advanced stages, while screening programs have not proven beneficial. Management of the advanced stages (FIGO III and IV), which constitute the majority of diagnoses, usually consists of platinum-based chemotherapy and cytoreductive surgery (primary or interval) followed by maintenance therapy. Currently, the standard-of-care for advanced newly diagnosed HGSE ovarian cancer, as per international medical societies, starts with upfront cytoreductive surgery, followed by platinum-based chemotherapy (mostly carboplatin and paclitaxel) and/or anti-angiogenic agent bevacizumab, then maintenance therapy with a poly(ADP-ribose) polymerase (PARP) inhibitor with/without/or bevacizumab (continued). PARP inhibitor use depends on the patient’s genetic signature, mainly the breast cancer gene (BRCA) mutation and the homologous recombination deficiency (HRD) status. Therefore, genetic testing is recommended at diagnosis to inform treatment and prognosis.In line with the evolving standard-of-care for ovarian cancer, a panel of experts in treating advanced ovarian cancer convened to lay down practical recommendations on the management of advanced ovarian cancer in Lebanon; since the currently applicable guidelines by the Lebanese Ministry of Public Health for cancer treatment have not been updated yet to reflect the treatment paradigm shift brought upon by the development and approval of PARP inhibitors. The current work reviews the leading clinical trials on PARP inhibitors (as maintenance for newly diagnosed advanced and platinum-sensitive relapsed ovarian cancer), presents international recommendations, and proposes treatment algorithms for optimal local practice